SpringWorks Therapeutics, Inc. - common stock (SWTX)
46.16
+1.45 (3.23%)
NASDAQ · Last Trade: Apr 28th, 2:54 PM EDT
Detailed Quote
Previous Close
44.72
Open
46.12
Bid
46.16
Ask
46.17
Day's Range
46.06 - 46.20
52 Week Range
28.21 - 62.00
Volume
72,736,119
Market Cap
2.27B
PE Ratio (TTM)
-18.92
EPS (TTM)
-2.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,917,251
Chart
About SpringWorks Therapeutics, Inc. - common stock (SWTX)
Springworks Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for underserved patient populations, particularly in the field of rare diseases and oncology. The company utilizes its proprietary drug development platform to identify and advance novel treatments, focusing on precision medicine approaches. By leveraging its expertise in biomarker-driven strategies, Springworks aims to bring transformative therapeutics to market, addressing significant unmet medical needs and improving the quality of life for patients dealing with complex health challenges. Read More
Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.
The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks shareholders.
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) –
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025.
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.
Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.
